Search:
Computing and Library Services - delivering an inspiring information environment

Assessment of different methods of inhalation from salbutamol metered dose inhalers by urinary drug excretion and methacholine challenge

Tomlinson, H.S., Corlett, S.A., Allen, M.B. and Chrystyn, Henry (2005) Assessment of different methods of inhalation from salbutamol metered dose inhalers by urinary drug excretion and methacholine challenge. British Journal of Clinical Pharmacology, 60 (6). pp. 605-610. ISSN 1365-2125

[img] PDF
Restricted to Registered users only

Download (106kB)

    Abstract

    Methods to determine the lung delivery of inhaled bronchodilators from metered dose inhalers include urinary drug excretion 30 min post inhalation and methacholine challenge (PD20). We have compared these two methods to differentiate lung delivery of salbutamol from metered dose inhalers using different inhalation methods.

    Methods
    In phase 1 of the study, on randomized study days, 12 mild asthmatics inhaled placebo, one and two 100 µg salbutamol doses from a breath actuated metered dose inhaler, in randomized fashion on different days. In phase 2, they inhaled one 100 µg salbutamol dose from a metered dose inhaler using a SLOW (20 l min1) and a FAST (60 l min1) inhalation technique and a slow inhalation delayed until after they had inhaled for 5 s (LATE). Urinary excretion of salbutamol (0–30 min) and PD20 were measured after each dose.

    Results
    Following placebo, one and two 100 µg salbutamol doses, the geometric mean for PD20 was 0.10, 0.41 and 0.86 mg respectively and the mean (SD) urinary drug excretion after one and two doses was 2.25 (0.65) and 5.37 (1.36) µg, respectively. After SLOW, FAST and LATE inhalations the geometric mean for PD20 was 0.50, 0.40 and 0.42 mg, respectively, and mean (SD) salbutamol excretion was 2.67 (0.84), 1.90 (0.70) and 2.72 (0.67) µg, respectively. Only the amount of drug excreted during the FAST compared with the SLOW and LATE inhalations showed a statistical difference (95% confidence interval on the difference 0.12, 1.54 and 0.06,1.59 µg, respectively).

    Conclusions
    Urinary salbutamol excretion but not PD20 showed differences between the inhalation methods used. When using a metered dose inhaler slow inhalation is better and co-ordination is not essential if the patient is inhaling when they actuate a dose of the drug.

    Item Type: Article
    Additional Information: © 2005 Blackwell Publishing Ltd
    Uncontrolled Keywords: bronchoprovocation, inhalation methods, salbutamol, urinary excretion
    Subjects: R Medicine > RS Pharmacy and materia medica
    Schools: School of Applied Sciences
    References:

    1 Chrystyn H. Methods to identify drug deposition in the lungs following inhalation. Br J Clin Pharmacol 2001; 51: 289–99.
    Synergy, Medline, ISI, CSA
    2 Hindle M, Chrystyn , H. Determination of the relative bioavailability of salbutamol to the lung following inhalation. Br J Clin Pharmacol 1992; 34: 311–5.
    Medline, ISI, Chemport, CSA
    3 Tomlinson HS, Corlett SA, Chrsytyn H. Dose–response relationship and reproducibility of urinary salbutamol excretion during the first 30 minutes after an inhalation. Br J Clin Pharmacol 2003; 56: 225–7.
    Synergy, Medline, ISI, CSA
    4 Adams WP, Poochikian G, Taylor AS, Patel RM, Burke GP, Williams , RL. Regulatory aspects of modifications to innovator bronchodilator metered dose inhalers and development of generic substitutes. J Aerosol Med 1994; 7: 119–34.
    Medline, CSA
    5 Barnes PJ, Pride NB. Dose–response curves to inhaled β-adrenoceptor agonists in normal and asthmatic subjects. Br J Clin Pharmacol 1983; 15: 677–82.
    Medline, ISI
    6 Creticos PS, Adams WP, Petty BG, Lewis LD, Singh GJ, Khattignavong AP, Molzon JA, Martinez MN, Lietman PS, Williams RL. A methacholine challenge dose–response study for development of a pharmacodynamic bioequivalence methodology for albuterol metered dose inhalers. J Allergy Clin Immunol 2002; 110: 713–20.
    CrossRef, Medline, ISI, CSA
    7 Juniper EF, Frith PA, Dunnet C, Cockroft DW, Hargreave FE. Reproducibility and comparison of responses to inhaled histamine and methacholine. Thorax 1978; 33: 705–10.
    Medline, ISI, Chemport
    8 Chrystyn H, Corrado OJ, Brownlee K, Kanthapillai P, Pearson S, Chetcuti P, Tarsin W. Inhalation rates of asthmatic children (CHILD) and adults and of chronic obstructive pulmonary disease (COPD) patients through inhalers. Am J Resp Crit Care Med 2002; 165(Suppl): A192.
    9 Hindle M, Newton DAG, Chrystyn H. Investigations of an optimal inhaler technique using urinary salbutamol excretion as a measure of relative bioavailability to the lung. Thorax 1993; 48: 607–11.
    Medline, ISI
    10 Newman SP, Weisz AW, Talaee N, Clarke SW. Improvement of drug delivery with a breath activated pressurised aerosol for patients with poor technique. Thorax 1991; 46: 712–6.
    Medline, ISI
    11 Farr SJ, Rowe AM, Rubsamen R, Taylor G. Aerosol deposition in the human lung following administration from a microprocessor controlled pressurised metered dose inhaler. Thorax 1995; 50: 639–44.
    Medline, ISI
    12 Beach JR, Young CL, Avery AJ, Stenton SC, Dennis , JH, Walters , EH, Hendrick , DJ. Measurement of airway responsiveness to methacholine. Thorax 1993; 48: 239–43.
    Medline, ISI
    13 Hartley-Sharp CJ, Booth H, Johns DP, Walters EH. Differences in aerosol output and airways responsiveness between the DeVilbiss 40 and 45 handheld nebulisers. Thorax 1995; 50: 635–8.
    Medline
    14 Yan K, Salome C, Woolcock AJ. Rapid method of measurements of bronchial responsiveness. Thorax 1983; 38: 854–8.
    Medline, ISI
    15 O'Connor BJ, Aikman SL, Barnes PJ. Tolerance to the non bronchodilation effects of inhaled β2-agonist in asthma. N Eng J Med 1992; 327: 1204–8.
    Medline, ISI, CSA
    16 Giannini D, Di Franco A, Bacci E, Dente FL, Taccola M, Vagaggini B, Paggiaro P. The protector effect of salbutamol inhaled using different devices on methacholine bronchoconstriction. Chest, 2000; 117: 1319–23.
    CrossRef, Medline, ISI
    17 Silkstone VL, Corlett SA, Chrystyn H. Relative lung and systemic bioavailability following inhalation from a metered dose inhaler, compared with a metered dose inhaler attached to a large Volume plastic spacer and a jet nebuliser. Eur J Clin Pharmacol 2002; 57: 781–6.
    CrossRef, Medline, ISI
    18 Lipworth BJ, Clark DJ. Lung delivery of non-CFC salbutamol via small Volume metal spacer and large Volume plastic spacer devices compared with an open vent jet nebuliser. Br J Clin Pharmacol 1998; 45: 160–3.
    Synergy, Medline, ISI, CSA
    19 Newman SP, Talaee N, Clarke SW. Salbutamol aerosol delivery in man with the Rondo-Spacer. Acta Ther 1991; 17: 49–50.
    20 Newman SP, Miller AB, Lennard-Jones TR, Moren F, Clarke SW. Improvement of pressurised aerosol deposition with Nebuliser spacer device. Thorax 1984; 39: 935–41.
    Medline, ISI
    21 Beasley R, Rafferty P, Holgate ST. Adverse reactions to the non-drug constituents of nebuliser solutions. Br J Clin Pharmacol 1988; 25: 283–7.
    Medline, ISI
    22 Elwood RK, Hugg JC, Pare PD. Airway response to osmolar challenge in asthma. Am Rev Respir Dis 1982; 121: 61.

    Depositing User: Briony Heyhoe
    Date Deposited: 10 Oct 2007
    Last Modified: 28 Jul 2010 19:21
    URI: http://eprints.hud.ac.uk/id/eprint/425

    Document Downloads

    Downloader Countries

    More statistics for this item...

    Item control for Repository Staff only:

    View Item

    University of Huddersfield, Queensgate, Huddersfield, HD1 3DH Copyright and Disclaimer All rights reserved ©